Akorn Inc. gains new drug approval

BUFFALO GROVE -- Akorn Inc. announced Wednesday that the U.S. Food and Drug Administration granted approval for Akorn's application for Ofloxacin Ophthalmic Solution USP 0.3 percent. The solution is used to treat infections caused by bacteria in conjunctivitis and corneal ulcers. Annual sales for Ofloxacin were about $7.5 million in 2007, according to IMS sales data. Akorn manufactures and markets sterile specialty pharmaceuticals.